Cargando…
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review
Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non–ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443114/ https://www.ncbi.nlm.nih.gov/pubmed/37614581 http://dx.doi.org/10.1016/j.jaccao.2023.05.008 |
_version_ | 1785093753205161984 |
---|---|
author | Leong, Darryl P. Cirne, Filipe Aghel, Nazanin Baro Vila, Rocio C. Cavalli, Germano D. Ellis, Peter M. Healey, Jeff S. Whitlock, Richard Khalaf, Dina Mian, Hira Jolly, Sanjit S. Mehta, Shamir R. Dent, Susan |
author_facet | Leong, Darryl P. Cirne, Filipe Aghel, Nazanin Baro Vila, Rocio C. Cavalli, Germano D. Ellis, Peter M. Healey, Jeff S. Whitlock, Richard Khalaf, Dina Mian, Hira Jolly, Sanjit S. Mehta, Shamir R. Dent, Susan |
author_sort | Leong, Darryl P. |
collection | PubMed |
description | Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non–ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the risks and benefits of invasive cardiac interventions in affected patients. We review the benefit conferred by invasive cardiac interventions; the periprocedural considerations; the contemporary survival expectations of patients across several types of active, advanced malignancy; and the literature on cardiovascular interventions in these populations. Our objective is to develop a rational framework to guide clinical recommendations on the use of invasive cardiac interventions in patients with active, advanced cancer. |
format | Online Article Text |
id | pubmed-10443114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104431142023-08-23 Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review Leong, Darryl P. Cirne, Filipe Aghel, Nazanin Baro Vila, Rocio C. Cavalli, Germano D. Ellis, Peter M. Healey, Jeff S. Whitlock, Richard Khalaf, Dina Mian, Hira Jolly, Sanjit S. Mehta, Shamir R. Dent, Susan JACC CardioOncol State-of-the-Art Review Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non–ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the risks and benefits of invasive cardiac interventions in affected patients. We review the benefit conferred by invasive cardiac interventions; the periprocedural considerations; the contemporary survival expectations of patients across several types of active, advanced malignancy; and the literature on cardiovascular interventions in these populations. Our objective is to develop a rational framework to guide clinical recommendations on the use of invasive cardiac interventions in patients with active, advanced cancer. Elsevier 2023-07-11 /pmc/articles/PMC10443114/ /pubmed/37614581 http://dx.doi.org/10.1016/j.jaccao.2023.05.008 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | State-of-the-Art Review Leong, Darryl P. Cirne, Filipe Aghel, Nazanin Baro Vila, Rocio C. Cavalli, Germano D. Ellis, Peter M. Healey, Jeff S. Whitlock, Richard Khalaf, Dina Mian, Hira Jolly, Sanjit S. Mehta, Shamir R. Dent, Susan Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review |
title | Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review |
title_full | Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review |
title_fullStr | Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review |
title_full_unstemmed | Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review |
title_short | Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review |
title_sort | cardiac interventions in patients with active, advanced solid and hematologic malignancies: jacc: cardiooncology state-of-the-art review |
topic | State-of-the-Art Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443114/ https://www.ncbi.nlm.nih.gov/pubmed/37614581 http://dx.doi.org/10.1016/j.jaccao.2023.05.008 |
work_keys_str_mv | AT leongdarrylp cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT cirnefilipe cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT aghelnazanin cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT barovilarocioc cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT cavalligermanod cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT ellispeterm cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT healeyjeffs cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT whitlockrichard cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT khalafdina cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT mianhira cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT jollysanjits cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT mehtashamirr cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview AT dentsusan cardiacinterventionsinpatientswithactiveadvancedsolidandhematologicmalignanciesjacccardiooncologystateoftheartreview |